INmune Bio (NASDAQ: INMB) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Last week, we hosted INMB management meetings in New York and conclude that even early clinical success with any one of its programs would justify our valuation. We view INMB’s DN-TNF platform to be a highly rational and safe approach to several diseases that are increasingly associated with surreptitious chronic inflammation. Earlier stage cancer therapy INKmune has advantages to other NK cell therapies including no removal of patient NK cells, a one size fits all approach, and substantially lower COGS.”
To request access to the full report, visit http://nnw.fm/DXCr3
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their disease – immune priming platform and DN-TNF platform. The immune priming platform is a Natural Killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack residual disease – the cause of cancer relapse. The DN-TNF platform includes programs in cancer, neurodegenerative disease and NASH. INB03 modifies the tumor microenvironment which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors and trastuzumab. XPro1595 targets microglial activation, nerve cell death and synaptic dysfunction associated with neurodegenerative disease. LivNate modifies metabolic and immunologic pathology that contributes to the development and progression of NASH. For more information, visit the company’s website at www.INmuneBio.com.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
NetworkNewsWire is part of the InvestorBrandNetwork.